Table 3. Cox regression analysis for PFS... | American Society of Hematology

Table 3.

Cox regression analysis for PFS and OS in rituximab-treated DLBCL patients (n = 108)

	PFS			OS
	HR	95% CI	P	HR	95% CI	P
Univariate analysis
AUC₁ ≥9400 mg × h per liter	0.38	0.17-0.83	.011	0.17	0.05-0.60	.001
TMTV₀, cm³ (×10⁻²)	1.07	1.02-1.13	.005	1.03	0.98-1.09	.24
IPI (3-4)	2.01	0.91-4.42	.082	2.14	0.76-6.00	.15
Chemotherapy (CHOP)	0.81	0.39-1.70	.577	1.09	0.41-2.90	.87
Male	2.42	1.03-5.66	.042	2.30	0.81-6.48	.11
Age, y	1.02	0.99-1.05	.262	1.03	0.99-1.08	.17
Final model with exposure*
AUC₁ ≥9400 mg × h per liter	0.38	0.17-0.83	.011	0.17	0.05-0.60	.001

	PFS			OS
	HR	95% CI	P	HR	95% CI	P
Univariate analysis
AUC₁ ≥9400 mg × h per liter	0.38	0.17-0.83	.011	0.17	0.05-0.60	.001
TMTV₀, cm³ (×10⁻²)	1.07	1.02-1.13	.005	1.03	0.98-1.09	.24
IPI (3-4)	2.01	0.91-4.42	.082	2.14	0.76-6.00	.15
Chemotherapy (CHOP)	0.81	0.39-1.70	.577	1.09	0.41-2.90	.87
Male	2.42	1.03-5.66	.042	2.30	0.81-6.48	.11
Age, y	1.02	0.99-1.05	.262	1.03	0.99-1.08	.17
Final model with exposure*
AUC₁ ≥9400 mg × h per liter	0.38	0.17-0.83	.011	0.17	0.05-0.60	.001

Final model includes significant covariates in the multivariate analysis.